Arbutus reports ~$123M cash, plans imdusiran Phase 2b in H1 2025; reduces burn to $47-50M

Arbutus Biopharma Corp

Cash, equivalents & investments ~$123M as of Dec 31, 2024; 2024 net cash burn ~$65M; 2025 burn expected $47-50M.
Plans placebo-controlled Phase 2b trial of imdusiran + interferon + NA in HBeAg-negative cHBV with HBsAg ≤1000 IU/mL in H1 2025; target N=170.
IM-PROVE I Phase 2a showed 50% functional cure (3/6) in HBeAg-negative patients with baseline HBsAg <1000 IU/mL; 25% overall.
AB-101 oral PD-L1 Phase 1a/1b Part 3 (28-day repeat doses) data expected in H1 2025; next steps determined after.
LNP litigation: claim construction hearing for Pfizer/BioNTech on Dec 18, 2024; Moderna trial set for Sept 24, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.